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Abstract
Background: Breast cancer risk increases drastically in individuals carrying a germline BRCA1 mutation. The
exposure to ionizing radiation for diagnostic or therapeutic purposes of BRCA1 mutation carriers is counterintuitive,
since BRCA1 is active in the DNA damage response pathway. The aim of this study was to investigate whether
healthy BRCA1 mutations carriers demonstrate an increased radiosensitivity compared with healthy individuals.
Methods: We defined a novel radiosensitivity indicator (RIND) based on two endpoints measured by the G2
micronucleus assay, reflecting defects in DNA repair and G2 arrest capacity after exposure to doses of 2 or 4 Gy. We
investigated if a correlation between the RIND score and nonsense-mediated decay (NMD) could be established.
Results: We found significantly increased radiosensitivity in the cohort of healthy BRCA1 mutation carriers
compared with healthy controls. In addition, our analysis showed a significantly different distribution over the RIND
scores (p = 0.034, Fisher’s exact test) for healthy BRCA1 mutation carriers compared with non-carriers: 72 % of
mutation carriers showed a radiosensitive phenotype (RIND score 1–4), whereas 72 % of the healthy volunteers
showed no radiosensitivity (RIND score 0). Furthermore, 28 % of BRCA1 mutation carriers had a RIND score of 3 or 4
(not observed in control subjects). The radiosensitive phenotype was similar for relatives within several families, but
not for unrelated individuals carrying the same mutation. The median RIND score was higher in patients with a
mutation leading to a premature termination codon (PTC) located in the central part of the gene than in patients
with a germline mutation in the 5′ end of the gene.
Conclusions: We show that BRCA1 mutations are associated with a radiosensitive phenotype related to a
compromised DNA repair and G2 arrest capacity after exposure to either 2 or 4 Gy. Our study confirms that
haploinsufficiency is the mechanism involved in radiosensitivity in patients with a PTC allele, but it suggests that
further research is needed to evaluate alternative mechanisms for mutations not subjected to NMD.
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Background
Breast cancer (BC) is the most common malignancy in
the Western world (http://www.who.int/cancer/detection/
breastcancer/en/). Approximately 15 % of all patients with
BC have at least one relative affected by BC. About 15 %
of all familial BCs can be attributed to a mutation in the
BRCA1 or BRCA2 gene [1]. Since the discovery of BRCA1,
many different functions have been attributed to this pro-
tein. In its function as a tumour suppressor gene, BRCA1
plays a crucial role in DNA double-strand break
(DSB) repair pathways (reviewed in [2, 3]). BRCA1 is,
for instance, important in homologous recombination
(HR), a pathway for repair of DSB in late S and G2
phases of the cell cycle [4–6]. BRCA1 also plays an
important role in the G2/M checkpoint control, allow-
ing the cell to repair DNA damage before proceeding
to the next phase of the cell cycle [7].
Carriers of a heterozygous BRCA1 mutation may show
enhanced radiosensitivity associated with an increased
carcinogenic risk after exposure to diagnostic or thera-
peutic ionizing radiation (IR). Several studies have
shown that exposure to diagnostic X-rays may cause
cancer in healthy BRCA1 mutation carriers [8–11],
whereas researchers in other studies could not detect a
positive association between exposure to IR and breast
cancer risk in BRCA1/2 mutation carriers [12–15]. Also,
researchers analysing the impact of (adjuvant) radiother-
apy on breast cancer risk in BRCA1 and BRCA2 muta-
tion carriers reported no univocal conclusion [16]. The
contradictory data obtained in these studies are due
mainly to the constraints in the design of the performed
studies.
Since long-term studies of the effect of exposure to IR
in mutation carriers are difficult to set up and are re-
puted to be unethical, it is clear that more empiric data
are needed to determine in vitro the radiosensitivity of
patients carrying a germline mutation. To date, research
has yielded contradictory results [17–26].
The G0 micronucleus assay performed on peripheral
blood lymphocytes exposed to in vitro doses of 2 to
4 Gy is frequently used to assess chromosomal radiosen-
sitivity. However, this assay is not optimized to detect
defects in DSB repair activated during the G2 phase of
the cell cycle or the G2/M checkpoint, two processes in
which BRCA1 plays a major role because irradiation
takes place in the G0 phase of the cell cycle.
We previously reported a modified micronucleus
(MN) assay optimized to detect defects in the S or G2 phase
of the cell cycle. This assay efficiently detected increased ra-
diosensitivity in a patient with a mild form of ataxia-
telangiectasia (A-T) and in heterozygous relatives [27].
In the present study, we applied the G2 micronucleus
assay to further elucidate whether healthy BRCA1 muta-
tion carriers are characterized by an increased in vitro
radiosensitivity. The endpoints of the study were (1)
micronucleus yields and (2) G2/M checkpoint efficiency
ratio. Both endpoints were assessed after irradiating
phytohaemagglutinin (PHA)-stimulated peripheral blood
lymphocytes with doses of 2 Gy and 4 Gy. With this assay,
we assessed the mean differences in radiosensitivity for
heterozygous BRCA1 mutation carriers compared with
healthy volunteers. We also scored the overall radiosensi-
tivity in each mutation carrier using a radiosensitivity indi-
cator (RIND) scoring system. In addition, as our BRCA1
population consisted of individuals carrying different
BRCA1 mutations, we investigated if there was a link be-
tween radiosensitivity and the degree of nonsense-
mediated decay (NMD) of the specific mutant allele.
Methods
Sample collection
Blood samples were collected from individuals consult-
ing the clinic of the Centre for Medical Genetics, Ghent
University Hospital, Belgium (CMGG). Both ethylenedi-
aminetetraacetic acid (EDTA) and heparin blood sam-
ples were collected. EDTA samples were used for
mutation analysis at CMGG, whereas the G2 MN assay
was performed on heparinized blood samples. In
addition, we collected heparinized blood samples from
healthy volunteers (n = 20) without a personal or family
history of BC to determine the normal distribution of
micronucleus yields in controls. Lymphocytes were iso-
lated from the blood samples using Lymphoprep™
(STEMCELL Technologies, Vancouver, BC, Canada) and
were preserved in liquid nitrogen for analysis of NMD of
the mutant allele. For a number of mutation carriers (n
= 4) and healthy volunteers (n = 7), a second blood sam-
ple was taken to determine the reproducibility of the re-
sults obtained with the G2 MN assay at different time
points.
This study was approved by the ethics committee of the
Ghent University Hospital (B670201111641 d.d. 20/09/
2011). All study participants (n = 18) were counselled by
clinical geneticists in the context of a predictive (n = 16)
or diagnostic (n = 2) test for hereditary BC and signed an
informed consent form. Two of the eighteen BRCA1 mu-
tation carriers had developed BC, but their cancer treat-
ment had finished more than 2 years ago; these women
are both carriers of a substitution affecting the start codon
(M01 and M02). The mean ages of the mutation carriers
and healthy volunteers were 40.9 and 35.4 years, respect-
ively (p = 0.26, t test).
Molecular analysis
All patients selected for this study had a family history of
breast and/or ovarian cancer and a BRCA1 germline
mutation. Targeted analysis for the familial mutation was
performed by direct sequencing on two independently
Baert et al. Breast Cancer Research  (2016) 18:52 Page 2 of 12
extracted DNA samples. No molecular analyses were per-
formed in healthy volunteers, owing to absence of per-
sonal or familial anamnesis for BC.
G2 micronucleus assay
For the G2 MN assay, a large blood culture was set up in
the presence of the mitogen PHA. PHA stimulates T-
lymphocyte division, resulting in a population of cycling
lymphocytes (G1, S1, G2 and M phase) after 3 days of in-
cubation, when the blood culture is irradiated. On the
contrary, in the G0 MN assay, blood is first irradiated
and then cultured in the presence of PHA, resulting in
the irradiation of T lymphocytes in G0 phase. The
addition of cytochalasin B (cyto B), an agent that blocks
cytokinesis, to the blood cultures allows the identifica-
tion of first-division cells as binucleated (BN) cells. A
non- or misrepaired DSB can result in an acentric
chromosomal fragment, which is detected as a micronu-
cleus in the cytoplasm of the BN cell [17, 28].
More precisely, for the G2 MN assay, a 50-ml blood cul-
ture was set up using 5 ml of heparinized blood, 45 ml of
complete RPMI (RPMI with 1 % L-glutamine and 0.5 %
penicillin/streptomycin) containing 10 % foetal calf serum
(FCS) and 1 ml of PHA (all Gibco®; Thermo Fisher, Rock-
ford, IL) in a T75 culture flask [27]. This large culture was
set up to avoid interculture variation during the first days of
incubation. After 3 days, the culture was split, and sham ir-
radiations as well as irradiations with 2 and 4 Gy 60Co
gamma rays were performed. An overview of the experi-
ments is shown in Fig. 1a. Immediately after irradiation,
cyto B (6 μg/ml; Sigma-Aldrich, St. Louis, MO, USA) was
added. To half of the irradiated cultures, caffeine (CAF,
4 mM; Sigma-Aldrich), an agent that abrogates the G2/M
checkpoint, was added to determine the G2/M checkpoint
efficiency ratio [29, 30]. On the basis of 5-bromo-2′-deox-
yuridine (BrdU) results obtained in our previous study on
ATM [27] and new experiments performed for this study,
a post-irradiation incubation period of 8 h was selected
for detecting DNA damage induced in cells in G2 phase
(Fig. 1b). The cultures were then treated with 75 mM KCl
and fixed once using a combination of methanol, acetic
acid and Ringer’s solution (9 g NaCl + 0.42 g KCl + 0.24 g
CaCl2 for 1 L of dH2O) (ratio 4/1/5, 4 °C) and thrice with
methanol and acetic acid (ratio 4/1, 4 °C). Finally, the cell
suspension was concentrated and spread on slides.
After 4′,6-diamidino-2-phenylindole staining, the
slides were scanned with a Metafer 4 (MN score soft-
ware module; MetaSystems; Altlussheim, Germany).
This automated image analysis system selects BN cells
and determines the number of MN per BN cell (see
Fig. 1a). For each condition, two cultures were set up
and two slides per culture were analysed. A minimum of
600 BN cells were scored on each coded slide for the
presence of MN. BN and MN selected in the automated
setting were manually checked for false-positives and
false-negatives. To determine the G2/M checkpoint effi-
ciency ratio, the quotient was determined for the MN
yield obtained in the presence versus the absence of caf-
feine (MNCaf+/MNCaf−). The lower this ratio was, the
more radiosensitive an individual was.
To assess the overall radiosensitive phenotype of each
patient, a RIND score was calculated. The mean and
standard deviation (SD) of the micronucleus yield and
the G2/M checkpoint efficiency ratio assessed in the co-
hort of healthy volunteers served to determine cut-offs
to define the radiosensitivity of individual BRCA1 muta-
tion carriers. An individual value equal to or greater than
the mean MN yields in controls + 1 SD scored 1 point
(colour-coded orange). A value equal to or greater than the
mean MN yields of controls + 2 SD scored 2 points
(colour-coded red). An individual value less than the mean
of controls + 1 SD was scored as naught (colour-coded
white). For the G2/M checkpoint, a similar conversion of
the data was performed, with a value less than the mean
checkpoint ratio assessed in controls − 1 SD scored 1 point
(colour-coded orange) and the mean− 2 SD scored 2 points
(color-coded red). An individual value greater than the
mean of controls− 1 SD was scored as naught (colour-
coded white). The combined scores from MN yields (0, 1
or 2 points) and checkpoint ratios (0, 1 or 2 points) were
then added to form a single RIND score (range 0–4).
Analysis of the cell-cycle phase at time of irradiation
BrdU was added to blood cultures of three individuals to
analyse the phase of the cell cycle at the time of irradi-
ation. BrdU (0.01 mM; Sigma-Aldrich) was added to the
cultures immediately after irradiation. Binucleated cells
that incorporated BrdU during synthesis were in S or G1
phase of the cell cycle at the moment of irradiation,
whereas BrdU-negative binucleated cells were irradiated
in G2 phase. We corrected for daughter nuclei incorporat-
ing BrdU after binucleation by adding BrdU 2 h before fix-
ation to another subset of cultures. BrdU was visualized by
fluorescence immunostaining with a monoclonal BrdU-
specific antibody (M0744; Dako, Carpinteria, CA, USA).
Analysis of the stability of the mutant allele
For this experiment, 2 × 106 frozen lymphocytes were
thawed and cultured in a mix of 1 ml of cRPMI, FCS
(10 %), 2-mercaptoethanol (0.1 %, Gibco®) and sodium
pyruvate (1 %; Life Technologies; Carlsbad, CA, USA).
PHA (10 μl/ml) was added to stimulate cell division. At
day 7, whole RNA was extracted using the QIAamp®
RNeasy Mini Kit (QIAGEN, Valencia, CA, USA) accord-
ing to the manufacturer’s instructions. Four hours before
extraction, all cultures were split in two, and puromycin
(200 μg/ml; Sigma-Aldrich) was added to one part.
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Puromycin was added to avoid NMD, a pathway respon-
sible for the degradation of aberrant mRNA [31].
The total RNA and purity was measured using the
DropSense96 reader (TRINEAN, Gentbrugge, Belgium).
The RNA was converted into complementary DNA
(cDNA) using the iScript™ cDNA Synthesis Kit (Bio-Rad
Laboratories, Hercules, CA, USA). When RNA was ex-
tracted from cultures with puromycin, the converted
cDNA is referred to as cDNAp. Before this cDNA syn-
thesis, samples were treated with DNase (Heat&Run Kit;
ArcticZymes, Tromsø, Norway) to remove any possible
remaining genomic DNA (gDNA).
To determine the ratio of the mutant BRCA1 allele ver-
sus the wild-type (WT) allele at the mRNA level, we per-
formed polymerase chain reaction (PCR) amplification
and Sanger sequencing of the amplicon harbouring the
germline mutation and a heterozygous single-nucleotide
polymorphism (SNP) (c.2311 T > C), if present. An over-
view of the primers used can be found in Additional file 1.
Sanger sequencing was performed using the BigDye® Ter-
minator Cycle Sequencing Kit (Life Technologies). PCR
was followed by ethanol precipitation, and fragments were
dissolved in a mix of Hi-Di™ formamide (10 μl; Life Tech-
nologies) and GeneScan™ 500 LIZ™ Size Standard (0.5 μl;
Applied Biosystems, Foster City, CA, USA). The frag-
ments were analysed on the ABI PRISM® 3730KL Genetic
Analyzer (Life Technologies). Results were evaluated using
GeneMapper® software (Applied Biosystems) for visual in-
spection and determination of the ratio of the peak
heights representing the WT and mutant alleles, respect-
ively (Additional files 2 and 3). Data were normalized with
a control peak in the near vicinity. To confirm the results,
the PCR amplicons were also sequenced with the sequen-
cing by synthesis technology on a MiSeq instrument
(Illumina, San Diego, CA, USA). The library preparation
was performed using an adapted Nextera XT protocol
(Illumina) as described by De Leeneer et al. [32]. Reads
were mapped with CLC Genomics Workbench (CLC bio/
QIAGEN, Aarhus, Denmark). The variant allele frequency
(VAF) (which reflects the ratio of WT versus mutant al-
lele) of both the mutation and a SNP (if available) was de-
termined in the mutation carriers and in controls without
a germline BRCA1 mutation.
Results
Analysis of the cell-cycle phase at time of irradiation
On the basis of data reported in the literature, the cell
cycle of proliferating lymphocytes takes between 18 and
Fig. 1 Design of the G2 micronucleus (MN) assay and overview of the cell cycle. a Left: Day 0: setup of one 50-ml large blood culture for every
patient. Day 3: division of the cultures and subsequent irradiation. Addition of cytochalasin B and caffeine (CAF; if needed) immediately after
irradiation, followed by incubation during 8 h before harvesting. Right: 4′,6-diamidino-2-phenylindole-stained binucleated cell with micronucleus
generated with the Metafer4 system (MetaSystems). b Overview of the cell cycle for proliferating lymphocytes and approximate duration of the
different phases with indication of the applied post-irradiation incubation period (black). At the start of irradiation, all lymphocytes in the blood
culture were mononucleated. After a post-irradiation incubation of 8 h, the cultures were fixed and binucleated (BN) cells (cells that went through
one mitosis) were scored for the presence of MN
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22 h. The cell cycle is presented in Fig. 1b, and the mean
length for each phase is indicated [33, 34]. With the
BrdU immunostaining experiments, we determined that
a post-irradiation incubation time of 8 h after 2- or 4-Gy
irradiation resulted in blood cultures in which 80 %
(±13 %) and 87 % (±3 %) binucleated cells, respectively,
were in G2 phase (negative at BrdU staining) at the time
of irradiation. In sham-irradiated samples, the percent-
age of BrdU-negative binucleated cells was much lower
(56 ± 8 %). These observations suggest that synchronization
of the cells in G2 phase took place because of radiation-
induced G2 arrest. When caffeine, an agent that abrogates
the G2/M checkpoint [29], was added to the cultures, the
percentage of cells in G2 phase decreased (2 Gy 73 %± 6 %;
4 Gy 79 % ± 2 %). The high percentage of cells irradiated in
G2 phase indicates that the harvest of BN cells 8 h post-
irradiation is optimal.
Results of G2 MN assay
The MN yield obtained for the sham-irradiated samples
did not show a significantly different mean result be-
tween mutation carriers and healthy volunteers (Table 1
and Fig. 2). The mean values obtained for the radiosensi-
tivity analysis are shown in Table 1 and Fig. 2. In BRCA1
mutation carriers compared with healthy volunteers, a
significantly increased radiosensitivity was observed for
both endpoints at both radiation doses of 2 Gy and 4 Gy.
Our results also show that the 4 Gy dose point was the
most discriminative (highest significance based on p value)
for both endpoints. We thus selected this dose to deter-
mine the individual overall radiosensitive phenotype. Re-
sults of the mutation analysis and individual results
obtained for the two radiosensitivity endpoints upon 4 Gy
irradiation are shown in Table 2. Each value received a
colour code corresponding to a radiosensitivity score,
from which a RIND score was calculated.
Significantly different RIND values were found for
BRCA1 mutation carriers (median 2) and healthy
volunteers (median 0) (p = 0.0076, Mann-Whitney U
test). Figure 3 shows the distribution of the BRCA1 mu-
tation carriers and healthy control subjects for the five
different RIND scores. The distribution amongst the
RIND scores between the two groups is significantly dif-
ferent (p = 0.034, Fisher’s exact test). The significantly
different median and the significantly different distribu-
tion over the RIND scores obtained for both groups
point towards a difference in response to radiation.
Repeated assessments were performed on blood speci-
mens taken on two different occasions from a random
sample of seven healthy volunteers and four mutation
carriers to exclude intraindividual variations. Although
minor variations were observed, no significant differ-
ences were observed between repeated measurements
(p > 0.05 for both MN yield and G2/M checkpoint effi-
ciency; repeated-measures analysis of variance).
We also investigated whether relatives of the subjects
enrolled in this study, carrying the same mutation, had
similar RIND scores. Individuals with the same family
ID are known to be related (Table 2). For families BR-
32-0196, BR-32-1028 and BR-32-2256, we had access to
data and samples of several relatives. Both father and
daughter of family BR-32-1028 showed a RIND score of
3. The siblings from family BR-32-2256 show RIND
scores of 1 and 2, and we obtained scores of 0 and 1 for
the third-degree relatives in family BR-32-0196. We thus
conclude that there were no major differences in RIND
scores within families. However, different RIND scores
(ranging from 0–4) were observed between four individ-
uals carrying the same mutation (c.2359dup), but we
were unaware of a close relationship.
Analysis of the stability of the mutant allele and
correlation with the RIND score
The results of fragment analysis and massive parallel se-
quencing were comparable (Table 3). All results for
cDNA, but not for gDNA, analyses are obtained by in
Table 1 Mean micronuclei yields and G2/M checkpoint efficiency ratios obtained with the G2 micronucleus assay
Micronucleus yield (MN/1000 BN) G2/M checkpoint efficiency (MNCAF
+/MNCAF−)
0 Gy 2 Gy 4 Gy 2 Gy 4 Gy
Healthy volunteers
Mean 15 61 91 2 3.1
SD 10 21 29 0.5 0.8
SEM 2 5 7 0.1 0.2
BRCA1 mutation carriers
Mean 16 83 128 1.6 2.2
SD 7 31 45 0.5 0.5
SEM 2 7 10 0.1 0.1
p Value (two-sided t test) 0.83 0.019 0.004 0.01 0.0002
BN binucleated cell, CAF caffeine, MN micronucleus or micronuclei, SD standard deviation
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duplicate experiments. The results of the MiSeq analysis
are expressed as the VAF in percent; 50 % means equal
expression of both alleles. The results of the fragment
analysis are shown as a ratio of peak heights of mutant
to WT allele. A value of 1 equals no loss of expression of
the mutant allele. cDNA samples not treated with puro-
mycin were scored as “evidence of NMD” (Table 3) when
an average VAF ≤31 % or a ratio of peak heights <0.7 was
obtained. We observed more variation for deletions/inser-
tions than for substitutions. This can be explained by the
more complex mapping of reads containing deletions/du-
plications. A large deletion and software struggling to map
correctly to the reference sequence explains a VAF <50 %
for gDNA in some patients (Table 3). Nevertheless, a drop
in VAF for cDNA and not for cDNA with puromycin can
still be distinguished.
For M02, M08 and M15, no lymphocytes were avail-
able to perform this assay. However, as we had access to
cDNA from other individuals with the same mutation,
we were able to gain insight into the stability of the mu-
tant mRNA for these three mutation carriers. For M16,
no gDNA data could be obtained; information with re-
gard to mutant mRNA stability for this mutation carrier
was obtained via cDNAp and M17.
Premature termination codon alleles in the central part of
the gene
For all truncating mutations studied in the central part
of the gene (7 unique mutations in 15 individuals), we
found evidence for NMD. In general, 25–30 % residual
truncated mRNA was detected in carriers of a premature
termination codon (PTC) mutation. Ten of fifteen pa-
tients with a truncating allele showed a radiosensitive
phenotype (RIND score 1–4, median 1).
Mutations located in the 5′ part of the gene
For mutations in the 5′ part of the gene (n = 3), we have
no evidence for NMD. The effect at the mRNA level for
the c.212 + 3A > G splice-site mutation has previously
been studied with quantitative PCR by our group. We
showed that no full-length transcript is formed, but that
it leads to a significantly increased expression of an
Fig. 2 Mean micronucleus (MN) yields and G2/M checkpoint efficiency ratios obtained with the G2 MN assay in healthy volunteers and BRCA1
mutation carriers. Significance was determined with a two-sided t test. p Values for each of the endpoints and dose points are indicated in the
graph. Error bars represent the standard error of the mean. BN binucleated cell, Caf caffeine
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Table 2 Results of mutation screening and radiosensitivity assessment for each individual
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alternative transcript (out of frame skip of 22 last nucle-
otides of exon 5; r.190_212del), which is not subjected
to NMD [35, 36]. As M03 is not heterozygous for any of
the tested common SNPs, results could not be re-
analysed with the approach described in this paper. Our
results for M03 showed a RIND score of 2, which can be
attributed to a decreased G2/M checkpoint efficiency.
For M01, carrier of the c.1A > G start codon mutation,
no decline of the mutant allele could be detected when
analysing the SNP data (Table 3). This suggests the con-
servation of the start codon or an alternative one. The
mutation itself could not be quantified, owing to the
presence of GC-rich areas near the start codon. The
introduction of an alternative start codon could give rise
to an aberrant protein with a dominant-negative effect
[37]. Interestingly, both individuals carrying a mutation
Fig. 3 The distribution (%) of healthy volunteers and BRCA1 mutation carriers over the different radiosensitivity indicator (RIND) scores
Table 3 Stability of the mutant allele
Fragment analysis MiSeq (VAF)
Donor RIND score Ratio peak height (mutant/WT allele) cDNA cDNAp gDNA Evidence for NMD?
M01 c.1A > G 3 0.7 (0.6–0.8) 49 (42–55) 52 (51–52) 49 (49–49) No
M02 c.1A > C 2 / / / / No
M03 c.212 + 3A > G 2 / / / / No
M04 c.1961del 0 0.4 (0.4–0.4) 29 (25–33) 47 (43–51) 47 (47–47) Yes
M05 c.2359dup 3 0.6 (0.6–0.6) 28 (25–31) 42 (38–45) 48 (48–48) Yes
M06 c.2359dup 2 0.5 (0.5–0.5) 24 (23–25) 44 (41–47) 50 (50–50) Yes
M07 c.2359dup 0 0.4 (0.4–0.5) 29 (27–30) 48 (30–67) 57 (55–59) Yes
M08 c.2359dup 4 / / / / Yes
M09 c.3331_3334del 1 0.4 (0.4–0.4) 25 (18–31) 44 (34–48) 49 (49–49) Yes
M10 c.3481_3491del 2 0.4 (0.4–0.4) 23 (16–30) 42 (28–52) 39 (32–46)a Yes
M11 c.3481_3491del 1 0.4 (0.3–0.5) 23 (16–32) 41 (23–54) 39 (34–44)a Yes
M12 c.3481_3491del 2 0.4 (0.4–0.4) 26 (16–34) 39 (28–50) 42 (35–49)a Yes
M13 c.3661G > T 1 0.5 (0.3–0.6) 29 (28–30) 50 (41–57) 50 (46–53) Yes
M14 c.3661G > T 0 0.4 (0.3–0.4) 31 (29–32) 52 (52–52) 50 (50–50) Yes
M15 c.3661G > T 0 / / / / Yes
M16 c.4327C > T 3 0.5 (0.5–0.6) 24 (21–27) 51 (45–56) / Yes
M17 c.4327C > T 3 0.6 (0.4–0.7) 26 (21–30) 48 (44–53) 50 (50–50) Yes
M18 c.4931_4393delinsTT 0 0.4 (0.3–0.4) 30 (28–31) 37 (28–47) 52 (52–52) Yes
cDNA complementary DNA, cDNAp cDNA extracted in the presence of puromycin, gDNA genomic DNA, NMD nonsense mediated decay, RIND radiosensitivity
indicator, VAF variant allele frequency, WT wild type
aVAF <50 % for gDNA
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affecting the start codon had, respectively, RIND scores
of 3 and 2. A median RIND score of 2 was observed for
carriers of a mutation in the 5′ part of the gene.
Discussion
Our study shows a significantly increased radiosensitivity
in the group of healthy BRCA1 mutation carriers com-
pared with healthy controls for the two endpoints mea-
sured by the G2 MN assay for both doses of 2 and 4 Gy.
Our results indicate that radiosensitivity in heterozygous
BRCA1 mutation carriers is a complex phenotype linked
to defects in DNA damage repair, as well as to defective
G2 arrest capacity. These results are in agreement with
the studies performed by Pantelias and Terzoudi [30].
They applied the G2 chromatid break assay and reported
that the G2/M checkpoint efficiency ratio is a good par-
ameter for prediction of intrinsic radiosensitivity in A-T
and cancer patients.
In vitro radiosensitivity has previously been investi-
gated in patients with BC and BRCA1 mutation carriers.
Cardinale et al. recently published a meta-analysis com-
bining all in vitro case-control studies in which the G0
MN assay on peripheral blood lymphocytes was used to
analyse in vitro radiosensitivity in women with BC or
with a known or putative genetic predisposition to BC
[17]. Other cytogenetic assays, such as the chromosome
aberration and G2 chromatid break assay or survival as-
says, have also been applied to determine radiosensitivity
in a variety of cell types heterozygous for BRCA1 muta-
tions, using different irradiation protocols [18–26]. It is
difficult, however, to correctly compare the results of
these studies, as also concluded by Cardinale et al. [17],
owing to different experimental set-ups to analyse in
vitro radiosensitivity. However, despite the heterogeneity
of the studies, most of the data generated, including
ours, are suggestive of a different radiosensitive pheno-
type between BRCA1 heterozygous mutant cells and
control cells. Recent studies in which researchers investi-
gated more specifically the functionality of the HR path-
way in BRCA1 heterozygous cells by means of γ-H2AX
and RAD51 foci assays point towards a less efficient
DSB repair by HR. These findings further support the
evidence of increased radiosensitivity observed in
BRCA1 heterozygous cells when irradiated in the S or
G2 phase of the cell cycle and are compatible with hap-
loinsufficiency as the underlying mechanism [24, 25, 38].
The strength of our study is that radiosensitivity was ana-
lysed by means of two different endpoints obtained with a
G2-specific MN assay developed by our group.
The radiosensitivity results in this study were obtained
with doses of 2 and 4 Gy, which is considerably higher
than any lifetime cumulative dose received by mammog-
raphy screening. The average dose delivered to the breast
glandular tissue per mammographic screening session is
approximately 4 mGy [39]. Thus, direct extrapolation of
our radiosensitivity results to the risks of mammography
is not possible. Despite this limitation, our results may
suggest caution in the IR exposure of healthy tissues of
BRCA1 mutation carriers for diagnostic purposes. It is fur-
thermore noteworthy that recent studies have shown that
30-kV X-rays have a higher relative biological effect and
are thus more harmful than conventional high-kilovoltage
X-rays or 60Co gamma rays, on which current risk assess-
ment is based. This implies that each mammogram
may induce more DNA damage than commonly estimated
[40, 41]. The authors of several papers have suggested that
mammography screening might preferably be replaced by
magnetic resonance imaging to avoid IR before the age of
30 years [16] or 40 years [42] in BRCA1 mutation carriers.
In addition, and more appropriately, given the high
doses used in this assay, our results suggest caution
in the use of adjuvant radiotherapy following breast-
conserving surgery. In this respect, there is a need for
well-designed studies to assess the incidence of second
ipsi- or contralateral cancers upon adjuvant radiotherapy
in mutation carriers [16].
Since it was our aim to develop a radiosensitivity assay
applicable in a clinical setting, we performed the G2 MN
assay on peripheral blood samples, which can easily be
obtained during a genetic consult. Several studies have
demonstrated that radiosensitivity of an individual is also
detectable in cells of a type different from cells in which
the tumour develops [18, 43, 44]. The scoring system
with RIND scores varying between 0 and 4 allowed us to
assess overall radiosensitivity due to both DNA repair
and G2 arrest capacity of each mutation carrier (Table 2
and Fig. 3). With the help of this scoring system, we de-
termined that 72 % of our healthy volunteers showed no
radiosensitive phenotype. BRCA1 mutation carriers, on
the contrary, showed a distinct pattern towards higher
radiosensitivity. Seventy-two percent of all mutation car-
riers were found to be radiosensitive (RIND score 1–3).
Moreover, 28 % of BRCA1 mutation carriers had RIND
scores equal to 3 or 4, scores that were never observed
in healthy volunteers. This simple scoring system can be
valuable in assisting physicians in their decision-making
in clinical follow-up and for refinement of radiotherapy
at the individual level. Since our study is limited in sam-
ple size, a larger prospective study with blood samples of
BRCA1 mutation carriers will be undertaken to confirm
and prove the importance of an in vitro radiosensitivity
scoring system to assist clinical management of BRCA1
mutation carriers.
Haploinsufficiency has been suggested as the main
mechanism for hereditary breast carcinogenesis [45].
However, as NMD is not observed for mutations located
in the 5′ and 3′ parts of the gene [46], a dominant-
negative effect whereby the aberrant transcript abolishes
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the functionality of the WT allele cannot be excluded
(for review, see [37, 47]). We wanted to evaluate if either
or both mechanisms could influence the radiosensitivity
score. Information on the stability of the mutant allele at
the mRNA level was generated by both a fragment ana-
lysis and a novel massive parallel sequencing approach.
To our knowledge, this is the first time that next-
generation sequencing is applied to evaluate the level of
NMD. The approach we describe here is straightforward
and cost-effective for study of the relative expression of
two alleles in a single individual.
The majority of patients included in this study are het-
erozygous for a mutation located in the central part of
the gene leading to a PTC. These PTC-inducing muta-
tions result in a truncated mRNA, which can be de-
graded by NMD. Generally, we observed that the
mutated PTC allele was expressed at a ratio of 25–30 %
of the WT allele at the mRNA level. Our results are
consistent with the data of Anczuców et al. and Perrin-
Vidoz et al. [46, 47]. Both articles describe a similar
reduction of mRNA expression from PTC alleles in the
central part of the gene and demonstrate the involve-
ment of NMD in this decrease of mutant mRNA. A ra-
diosensitive phenotype in 10 of 15 mutation carriers
with a PTC allele undergoing NMD suggests haploinsuf-
ficiency as a mechanism leading to this phenotype in the
large majority of the individuals.
Equal expression of the WT and mutant alleles at the
mRNA level was observed in the patients with the start
codon mutation (M01 and M02). For the patient with
the c.212 + 3A > G mutation (M03), equal expression of
a full-length transcript and a transcript lacking the last
22 nucleotides of exon 5 was observed in previous re-
search by our group and confirmed by others [35, 36]. A
higher median RIND score in the individuals carrying a
mutation in the 5′ part of the gene, for which no NMD
could be detected, compared with individuals with a
PTC allele may point towards another mechanism in-
volved in the radiosensitive phenotype, such as a
dominant-negative effect. However, current knowledge
on translation of mutant alleles not subjected to NMD
into proteins is limited. Such detailed studies have not yet
been undertaken; in most studies demonstrating a role for
haploinsufficiency, BRCA1 mutation carriers are com-
pared as a group with non-carriers (e.g., [25, 38, 48]). Our
data suggest the need for larger studies involving different
types of mutations.
Unique to this radiosensitivity study compared with
others are that we had access to material from several in-
dividuals from one family and that we could also evaluate
the radiosensitive phenotype from several unrelated indi-
viduals carrying the same mutation. For four unrelated
carriers of a Belgian founder mutation c.2359dup
(p.Glu787fs*3), a large variation for the radiosensitive
phenotype based on the RIND score was observed (range
0–4) (Table 2). Repeated assessments on blood specimens,
taken on two different occasions from several individuals,
ruled out that the different RIND scores were due to
experimental variation. Given the smaller variation
between related individuals, and because of the pleio-
tropic effect of IR on DNA (for example, strand
breaks, fork stalling, base damage, DNA adducts [49–
51]), we are convinced that other genetic factors in-
fluence the radiosensitivity. In previous research, for
example, researchers have demonstrated the effect of
SNPs on individual sensitivity to radiation therapy
[52, 53]. In addition, our group has demonstrated the
influence of RAD51, Ku70 and Ku80 SNPs as modu-
lators of in vitro radiosensitivity in BRCA1 mutation
carriers and patients with BC [54, 55]. A larger study
and the inclusion of a control population with rela-
tives not harbouring the familial germline mutation
could generate important insights.
Conclusions
In our present study, using the G2 MN assay, we show
that healthy individuals carrying a germline mutation in
BRCA1 are more radiosensitive than healthy control
subjects after exposure to doses of 2 and 4 Gy. Seventy-
two percent of the BRCA1 mutation carriers showed a
radiosensitive phenotype, and 28 % of BRCA1 mutation
carriers had high RIND scores of 3 or 4. Analysis of the
mRNA stability of the mutant allele could not demon-
strate a clear link between nonsense-mediated decay of
the mutant allele and a radiosensitive phenotype.
This, combined with the similar radiosensitive pheno-
type observed for related individuals but not for unre-
lated individuals carrying the same mutation, is
indicative of the fact that additional genetic factors
besides the BRCA1 mutation may play a role in the
radiation response. Our study emphasizes the need
for large, prospective studies correlating the in vitro
findings and exposure to radiation with the risk of
developing breast cancer.
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